| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-712
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 |
| filingDate |
1998-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2002-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2002534353-A |
| titleOfInvention |
Methods and compounds for gene therapy of hyperlipidemia |
| abstract |
(57) [Summary]nThe present invention relates to introducing specific mutations into genes encoding three types of apolipoproteins Apo A1, Apo B and Apo E. Modifications of Apo A1 are those that introduce cysteine residues so that disulfide-bridged Apo A1 homodimers and Apo A1 / A2 heterodimers are formed. Modifications of Apo B introduce a stop codon or frameshift mutation that produces a truncated ApoB protein. Modifications of Apo E introduce specific point mutations that have been identified as protective. Production of these modified proteins in the subject's liver reduces the subject's risk of developing atherosclerosis. In certain embodiments, mutations in the gene are introduced by use of a chimeric mixed RNA / DNA double-stranded oligonucleotide. |
| priorityDate |
1998-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |